INDICATION AND IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is a prescription medicine used for the treatment of a known or suspected opioid overdose emergency with signs of breathing problems and severe sleepiness or not being able to respond. NARCAN® Nasal Spray is to be given right away and does not take the place of emergency medical care. Get emergency medical help right away after giving the first dose of NARCAN® Nasal Spray, even if the person wakes up.

NARCAN® Nasal Spray is safe and effective in children for known or suspected opioid overdose. Do not use NARCAN® Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in NARCAN® Nasal Spray.

What is the most important information I should know about NARCAN® Nasal Spray? NARCAN® Nasal Spray is used to temporarily reverse the effects of opioid medicines. The medicine in NARCAN® Nasal Spray has no effect in people who are not taking opioid medicines. Always carry NARCAN® Nasal Spray with you in case of an opioid overdose.

Use NARCAN® Nasal Spray right away if you or your caregiver think signs or symptoms of an opioid overdose are present, even if you are not sure, because an opioid overdose can cause severe injury or death. Signs and symptoms of an opioid overdose may include: unusual sleepiness and you are not able to awaken the person with a loud voice or by rubbing firmly on the middle of their chest (sternum); breathing problems including slow or shallow breathing in someone difficult to awaken or who looks like they are not breathing; the black circle in the center of the colored part of the eye (pupil) is very small, sometimes called “pinpoint pupils.” Lay the person on their back to receive a dose of NARCAN® Nasal Spray.

NARCAN® Nasal Spray is safe and effective in children for known or suspected opioid overdose. Get emergency medical help right away after giving the first dose of NARCAN® Nasal Spray, even if the person wakes up. NARCAN® Nasal Spray may be given while waiting for emergency medical help.

What should I tell my healthcare provider before using NARCAN® Nasal Spray? Before using NARCAN® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you have heart problems; are pregnant or plan to become pregnant. Use of NARCAN® Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use NARCAN® Nasal Spray; are breastfeeding or plan to breastfeed. It is not known if NARCAN® Nasal Spray passes into your breast milk.

Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, drugs, vitamins, and herbal supplements.

What are the possible side effects of NARCAN Nasal Spray? NARCAN® Nasal Spray may cause serious side effects, including:

- sudden opioid withdrawal symptoms which can be severe. In someone who has been using opioids regularly, opioid withdrawal symptoms can happen suddenly after receiving NARCAN® Nasal Spray and may include: body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, increased blood pressure.

Some patients may show aggressive behavior upon abrupt reversal of an opioid overdose. In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include: seizures, crying more than usual, and increased reflexes.

These are not all of the possible side effects of NARCAN® Nasal Spray. Call your doctor or healthcare provider for more information.

CLICK HERE FOR FULL PRESCRIBING INFORMATION

© 2022 Emergent Devices Inc. Plymouth Meeting, PA. All rights reserved. NARCAN® is a registered trademark of Emergent Operations Ireland Limited. Emergent Devices Inc. and Emergent Operations Ireland Limited are wholly-owned subsidiaries of Emergent BioSolutions Inc. PP-NAR4-US-00581 02/2022